Healthcare entity
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Drug Controller General of India (DCGI), the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Takeda Biopharmaceuticals India, all published on July 25, 2026.
Last mentioned: Jul 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Drug Controller General of India (DCGI), the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Takeda Biopharmaceuticals India, all published on July 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Takeda Biopharmaceuticals India. Shared-story counts are live from our verified record — not editorial picks.
DCGI's authorization of QDENGA brings India its first dengue vaccine, a no‑screening option that could reshape public health strategy. With the country bearing a third of the world's dengue cases, the vaccine promises to reduce hospitalizations and ease endemic pressure on healthcare systems.
Takeda Biopharmaceuticals India is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
